1. People's Republic of China Stocks

  2. •

    Basic Materials

  3. •

    Construction Materials
Zhejiang Jianfeng Group Co., Ltd.

Zhejiang Jianfeng Group Co., Ltd.

600668.SS
Zhejiang Jianfeng Group Co., Ltd.CN flagShanghai Stock Exchange
7.75
CNY
+0.17
- -
3.20BMarket Cap
Zhejiang Jianfeng Group Co., Ltd.
600668.SS
(Shanghai Stock Exchange)

Recent

price

7.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.21
3.98
4.03
5.25
5.45
5.43
5.77
6.83
8.14
8.61
7.87
9.23
8.66
6.94
6.93
6.23
6.82
Revenue per Share
0.32
0.65
0.4
0.49
0.68
0.48
0.69
0.84
1.42
1.76
1.42
2.24
0.7
0.23
0.26
1
1.64
Basic EPS, GAAP
-0.01
-0.2
-0.22
-0.15
0.39
-0.06
0.8
0.78
1.3
0.42
0.13
0.42
-0.18
-0.47
0.18
-1.1
-1.29
Free Cash Flow per Basic Share
0.12
0.11
0.19
0.23
0.26
0.32
0.23
0.3
0.17
0.31
0.3
0.36
0.45
0.16
0.13
0.14
0.14
Dividend per Share
1.46
2.08
2.37
2.72
3.17
3.4
3.92
4.5
5.74
7.2
8.26
10.55
10.87
10.81
11.02
12.2
12.66
Book Value per Share
2.7
3.33
3.55
4.1
4.85
5.08
5.69
6.27
7.58
8.98
10.45
12.43
12
11.59
11.62
12.53
13.04
Tangible Book Value per Share
413
414
409
410
414
416
412
414
413
412
413
412
411
417
415
412
413
Basic Weighted Avg Shares
1,325
1,645
1,649
2,151
2,257
2,259
2,379
2,827
3,362
3,548
3,247
3,805
3,560
2,893
2,876
2,568
2,816
Sales/Revenue/Turnover
7.47
13.42
6.84
8.71
11.18
8.04
11.04
16.09
20.72
19.95
17.88
14.68
9.43
4.09
6.79
1.82
8.11
Operating Margin (%)
55
66
61
81
87
99
107
110
117
128
144
179
201
223
276
285
- -
Depreciation Expense
133
269
164
202
283
201
285
348
589
725
584
924
288
94
108
412
678
Net Income, GAAP
12.01
15.72
14.27
16.11
16.25
18.58
17.23
21.99
20.37
15.76
14.42
17.45
23.89
33.04
34.13
11.92
9.57
Effective Tax Rate (%)
10.03
16.34
9.91
9.37
12.54
8.9
11.99
12.33
17.5
20.43
18
24.29
8.08
3.24
3.75
16.04
24.07
Profit Margin (%)
-150
-214
-416
-237
169
148
8
-61
172
350
252
253
-175
-19
-395
-190
116
Working Capital
156
38
9
383
681
596
574
253
100
200
92
66
25
352
17
28
72
LT Debt
1,258
1,556
1,646
1,896
2,237
2,324
2,552
2,824
3,450
4,080
4,721
5,511
5,585
5,469
5,532
5,848
6,093
Total Equity
5.04
9.54
4.72
6.62
7.11
4.7
6.72
10.31
14.65
13.84
10.1
8.37
4.31
1.3
2.11
0.65
3.18
Return on Invested Capital (%)
11.75
18.95
12.48
11.7
12.81
9.06
11.89
12.95
18.02
19.6
13.8
18.92
5.03
2.07
1.82
7.81
11.31
Return on Capital (%)
24.1
36.68
17.86
19.35
23.3
14.72
18.81
20.03
27.8
27.15
18.34
23.83
6.53
2.09
2.38
8.58
13.91
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
588
891
834
LT Borrowings
- -
6
62
LT Finance Leases
17
18
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
413
413
413
Market Capitalization
2,465
3,638
4,869

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,394
1,523
1,973
Cash, Cash Equivalents & STI
264
428
403
Accounts Receivable, Net
272
282
261
Inventories
401
410
410
Total Current Liabilities
1,789
1,985
1,857
Payables & Accruals
- -
- -
- -
ST Debt
588
891
834
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.95%
4.57%
5.72%
Free Cash Flow
-211.83%
-123.9%
-715.9%
Net Income, GAAP
35.53%
43.69%
281.43%
Sales/Revenue/Turnover
2.08%
-3.86%
-10.74%
Total Cash Common Dividend
-0.11%
-7.31%
3.33%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
602
757
663
854
2,876
2025
584
715
648
- -
2,568
2026
537
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.26
2025
1.41
- -
- -
- -
1
2026
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.13
2025
0.01
- -
- -
- -
0.14
2026
0.01
- -
- -
- -
- -
Similar Companies
Holcim Ltd (HOLN.SW)
Tongyang Inc. (001527.KS)
Michelmersh Brick Holdings plc (MBH.L)
Tipco Asphalt Public Company Limited (TASCO.BK)
CRH plc (CRG.IR)
Yamau Holdings Co., Ltd. (5284.T)
Business
Zhejiang Jianfeng Group Co., Ltd. (600668.SS) manufactures and distributes cement and pharmaceuticals in China, supplemented by health products, trade logistics, cables and hazardous chemicals. The company produces ordinary Portland cement, Portland slag cement, cement clinkers, silica cements; pharmaceuticals including cefmenoxime hydrochloride for injection, aspartate amlodipine tablets, paroxetine hydrochloride tablets, aceclofenac sustained-release tablets, sodium hyaluronate eye drops, olopatadine hydrochloride eye drops, antibiotics, cardiovascular and cerebrovascular drugs, antidepressants and ophthalmology drugs; health products such as grape seed extract, ginseng extract, apple extract anthocyanins, polyphenols, fruit and vegetable powders, broken fungus spore powder, lyophilized Tianma pieces, Sangge tea, black soya bean drinks, astragalus tablets and various soft capsules; cables including SYWV-75 series physical foamed cables, RVV series cables, network lines, HYA series communication cables and BV insulated wires. Its building materials operations span Zhejiang, Hubei, Yunnan and Guizhou provinces through subsidiaries such as Daye Jianfeng Cement Co., Ltd., while pharmaceutical distribution and retail focus on Zhejiang hospitals and patients via Jinhua Medicine Co., Ltd. and subsidiaries; health products serve domestic and international food, health and cosmetics industries. Founded in 1958 as Jinhua Cement Plant and headquartered at No. 88 Wujiang East Road, Jinhua, Zhejiang Province, the company transformed to a joint-stock system in 1988 and listed on the Shanghai Stock Exchange in 1993 as China's first cement listed firm. Subsidiaries include Zhejiang Jianfeng Pharmaceutical Co., Ltd., Tianjin Jianfeng Natural Products Research and Development Co., Ltd., Shanghai North Cara Medical Technology Co., Ltd. and Zhejiang Jianfeng Health Technology Co., Ltd. In recent developments, a wholly-owned subsidiary plans investment in a 3 million tons annual output production line; the board authorized a share buyback plan in April 2025 and an equity buyback for CNY 40 million; Daye Jianfeng Cement achieved national "green factory" status; and Jianfeng Pharmaceutical rehired Academician Wang Guangji as chief scientist while a subsidiary's esomeprazole product won a national procurement bid.